Gheissari Alaleh, Harandavar Maryam, Hildebrandt Friedhelm, Braun Daniela A, Sedghi Maryam, Parsi Nastaran, Merrikhi Alireza, Madihi Yahya, Aghamohammadi Farzaneh
Department of Pediatric Nephrology, Isfahan University of Medical Sciences, Esfahan, Iran.
Iran J Kidney Dis. 2015 Mar;9(2):119-25.
Nephronophthisis is of the most commonly inherited ciliopathies that leads to end-stage renal disease in children. The NPHP1 gene is the first identified gene responsible for nephronophthisis and related diseases. This study assessed mutations of the NPHP1 gene in 16 Iranian families with at least one member presenting features of nephronophthisis.
Fifty-seven patients diagnosed with chronic kidney disease or end-stage renal disease were referred to Imam Hossein Children Hospital, in Isfahan, Iran. The gene analysis study was carried on 16 patients and their first-degree relatives (40 DNA samples) suspicious of having nephronophthisis. The NPHP1 deletion analysis was performed for exons 5, 7, and 20 of the NPHP1 gene.
The patients' median age was 15 years. The mean and median age of the first presentation was 10.06 ± 2.59 years and 10.5 years, respectively. A homozygous deletion was identified in the NPHP1 gene spanning at least from exon 5 to exon 20 in two families. High-throughput mutation analysis identified a homozygous truncating mutation (c.1504C>T, p.R502*) in the NPHP5 in 5 families.
By combining NPHP1 deletion analysis with multiplex-polymerase-chain-reaction-based high-throughput mutation analysis we could identify the molecular disease-cause in 7 of 15 families from Iran. In 8 families, the molecular disease cause remained unknown.
肾单位肾痨是最常见的遗传性纤毛病之一,可导致儿童终末期肾病。NPHP1基因是首个被鉴定出与肾单位肾痨及相关疾病有关的基因。本研究评估了16个伊朗家庭中NPHP1基因的突变情况,这些家庭中至少有一名成员表现出肾单位肾痨的特征。
57名被诊断为慢性肾病或终末期肾病的患者被转诊至伊朗伊斯法罕的伊玛目侯赛因儿童医院。对16名疑似患有肾单位肾痨的患者及其一级亲属(40份DNA样本)进行了基因分析研究。对NPHP1基因的第5、7和20外显子进行了NPHP1缺失分析。
患者的中位年龄为15岁。首次出现症状的平均年龄和中位年龄分别为10.06±2.59岁和10.5岁。在两个家庭中,NPHP1基因中鉴定出至少从第5外显子到第20外显子的纯合缺失。高通量突变分析在5个家庭的NPHP5中鉴定出一个纯合截断突变(c.1504C>T,p.R502*)。
通过将NPHP1缺失分析与基于多重聚合酶链反应的高通量突变分析相结合,我们能够在来自伊朗的15个家庭中的7个家庭中确定分子致病原因。在8个家庭中,分子致病原因仍然未知。